Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial

Autor:	Padimac investigators, Laura Clifton-Hadley, Dunnya De-Silva, Treen C. M. Morris, Nicholas Counsell, Wei Yee Chan, Elizabeth H Phillips, Neil Rabin, Roger G. Owen, Gordon Cook, Rakesh Popat, Jamie Cavenagh, Ruth M. de Tute, Matthew Streetly, Mickey Koh, Nivette Braganca, Josephine Crowe, Kwee Yong, Stephen Schey, Toyin Adedayo, Claire Roddie
Rok vydání:	2021
Předmět:	Oncology Very Good Partial Response medicine.medical_specialty Chemotherapy business.industry Bortezomib medicine.medical_treatment Hematology medicine.disease Autologous stem-cell transplantation Internal medicine medicine In patient Stem cell business Dexamethasone Multiple myeloma medicine.drug
Zdroj:	British Journal of Haematology. 196
ISSN:	1365-2141 0007-1048
DOI:	10.1111/bjh.17903
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9900443f58e6b291b392e879118cad73 https://doi.org/10.1111/bjh.17903 Zobrazit plný text záznamu Plný text